NCT02231541

Brief Summary

The purpose of the study is to determine the effectiveness of treatment with very low frequency electromagnetic fields on the reduction of pain in patients with fibromylgia, disease presenting with widespread musculoskeletal pain usually associated with other symptoms such as stiffness, fatigue, sleep disturbances, depression, anxiety.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
37

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 8, 2014

Completed
24 days until next milestone

Study Start

First participant enrolled

September 1, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 4, 2014

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2015

Completed
Last Updated

June 8, 2015

Status Verified

September 1, 2014

Enrollment Period

3 months

First QC Date

August 8, 2014

Last Update Submit

June 4, 2015

Conditions

Keywords

FibromylgiaMagnetic FieldsPainVisual Analogue scale

Outcome Measures

Primary Outcomes (1)

  • Change of Visual Analogue Scale (VAS) from baseline to 12 weeks

    It is a scale for the assessment of pain and it's based on a ten point scale, where 0 means no pain and 10 the greatest pain ever both at rest and during movements.

    baseline, 4 weeks, 12 weeks

Secondary Outcomes (3)

  • Change of Fibromylgia Impact Questionnaire (FIQ) from baseline to 12 weeks

    baseline, 4 weeks, 12 weeks

  • Change of Fibromylgia Assessment Status (FAS) from baseline to 12 weeks

    baseline, 4 weeks, 12 weeks

  • Change of Health Assessment Questionnaire (HAQ) from baseline to 12 weeks

    baseline, 4 weeks, 12 weeks

Study Arms (2)

Very low frequency magnetic fields

EXPERIMENTAL

The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.

Device: Very Low Frequency Magnetic Fields

Turned off very low frequency magnetic fields

PLACEBO COMPARATOR

The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.

Device: Very Low Frequency Magnetic Fields

Interventions

The device is set to an analgesic program lasting about 30 minutes.

Also known as: ELF
Very low frequency magnetic fields

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Fibromyalgia diagnosed according to the criteria proposed by the American College of Rheumatology (ACR 2010)
  • Subjects aged between 18 and 60 years

You may not qualify if:

  • Pregnant patients
  • Patients with pacemaker or other metal implants
  • Systemic infectious disorders
  • Neoplastic disorders
  • Epilepsy
  • Severe heart disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Umberto I Hospital

Rome, 00165, Italy

Location

Related Publications (1)

  • Paolucci T, Piccinini G, Iosa M, Piermattei C, de Angelis S, Grasso MR, Zangrando F, Saraceni VM. Efficacy of extremely low-frequency magnetic field in fibromyalgia pain: A pilot study. J Rehabil Res Dev. 2016;53(6):1023-1034. doi: 10.1682/JRRD.2015.04.0061.

MeSH Terms

Conditions

FibromyalgiaPain

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Vincenzo Maria Saraceni

    Umberto I Hospital, Sapienza University of Rome

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
medical director

Study Record Dates

First Submitted

August 8, 2014

First Posted

September 4, 2014

Study Start

September 1, 2014

Primary Completion

December 1, 2014

Study Completion

March 1, 2015

Last Updated

June 8, 2015

Record last verified: 2014-09

Locations